Venous Leg Ulcers (Crural ulcer)：パイプライン分析（ヘルスケア市場レポート）H1 2013...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Venous Leg Ulcers (Crural ulcer) 8
Venous Leg Ulcers (Crural ulcer) Therapeutics under Development by Companies 10
Venous Leg Ulcers (Crural ulcer) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Venous Leg Ulcers (Crural ulcer) Therapeutics – Products under Development by Companies 17
Venous Leg Ulcers (Crural ulcer) Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Venous Leg Ulcers (Crural ulcer) Therapeutics Development 19
RegeneRx Biopharmaceuticals, Inc. 19
CytoTools AG 20
Healthpoint, Ltd. 21
Glycotex, Inc. 22
FirstString Research, Inc. 23
CoDa Therapeutics, Inc. 24
Adocia 25
Venous Leg Ulcers (Crural ulcer) – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
RGN-137 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GLYC-101 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DermaPro CI-05 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Biochaperone PDGF-BB – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HP802-247 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Nexagon – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LyphoDerm – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
LL-37 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Granexin – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Autologous Bone Marrow Derived Cells – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Venous Leg Ulcers (Crural ulcer) Therapeutics – Drug Profile Updates 45
Venous Leg Ulcers (Crural ulcer) Therapeutics – Discontinued Products 50
Venous Leg Ulcers (Crural ulcer) Therapeutics – Dormant Products 51
Venous Leg Ulcers (Crural ulcer) – Product Development Milestones 52
Featured News & Press Releases 52
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 52
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 52
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 53
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 54
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 55
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 56
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 56
Dec 20, 2004: RegeneRx Files With FDA For Second Phase II Clinical Trial 56
Jun 23, 2004: Sigma-Tau Conducts Phase II Clinical Trial In Europe With Tß4 For Venous Stasis Ulcers 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60